Profile data is unavailable for this security.
About the company
BEIJING TIANTAN BIOLOGICAL PRODUCTS CORPORATION LIMITED is a China-based company principally engaged in the biopharmaceutical businesses. The Company’s primary products include preventive products, blood products and other biological products, such as the influenza A (H1N1) vaccines (split, inactivated),hepatitis B vaccines, poliomyelitis vaccines, measles-mump-rubella (MMR) vaccines, encephalitis B vaccines, influenza vaccinations, bacterial vaccines, human serum albumin (HSA) and intravenous immunoglobulin (IVIG), among others. The Company mainly distributes its products within domestic markets and to Hong Kong markets.
- Revenue in CNY (TTM)5.11bn
- Net income in CNY1.16bn
- Incorporated1998
- Employees4.86k
- LocationBeijing Tiantan Biological Products Corp LtdNo. 2Shuangqiao Road B, Chaoyang DistrictBEIJING 100024ChinaCHN
- Phone+86 1 065439720
- Fax+86 1 065436770
- Websitehttps://www.tiantanbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 8.15bn | 973.25m | 35.43bn | 4.62k | 29.32 | 4.08 | -- | 4.35 | 1.27 | 1.27 | 10.60 | 9.09 | 0.744 | 3.12 | 3.24 | 1,765,208.00 | 8.71 | 8.96 | 13.06 | 12.80 | 43.68 | 40.82 | 11.70 | 10.67 | 1.62 | -- | 0.1381 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Hubei Jumpcan Pharmaceutical Co Ltd | 9.67bn | 2.99bn | 35.84bn | 5.23k | 11.93 | 2.51 | -- | 3.71 | 3.26 | 3.26 | 10.54 | 15.51 | 0.5504 | 3.66 | 4.60 | 1,848,716.00 | 17.05 | 16.23 | 22.52 | 20.88 | 79.76 | 82.64 | 30.98 | 24.42 | 3.01 | -- | 0.1275 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Beijing Tiantan Biological Products Corp | 5.11bn | 1.16bn | 50.67bn | 4.86k | 43.51 | 5.00 | -- | 9.92 | 0.7068 | 0.7068 | 3.10 | 6.15 | 0.3611 | 0.9104 | 171.46 | 1,051,960.00 | 11.18 | 11.71 | 16.00 | 16.50 | 52.26 | 49.39 | 30.97 | 27.71 | 3.41 | -- | 0.0094 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 38.97 |
| Shanghai Fosun Pharmaceutical (Group) | 40.69bn | 2.01bn | 57.62bn | 40.37k | 31.72 | 1.38 | -- | 1.42 | 0.7525 | 0.7525 | 15.24 | 17.36 | 0.368 | 2.90 | 5.28 | 1,007,829.00 | 2.32 | 4.31 | 3.83 | 7.01 | 46.73 | 50.71 | 6.31 | 10.65 | 0.79 | -- | 0.3818 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
| Beijing Tongrentang Co Ltd | 17.99bn | 1.72bn | 60.80bn | 16.78k | 35.32 | 4.48 | -- | 3.38 | 1.26 | 1.26 | 13.11 | 9.90 | 0.6079 | 1.23 | 10.82 | 1,072,010.00 | 8.84 | 8.20 | 16.50 | 16.17 | 45.32 | 46.59 | 14.55 | 13.33 | 2.28 | -- | 0.1632 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
Data as of Jun 07 2024. Currency figures normalised to Beijing Tiantan Biological Products Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY
10.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 41.70m | 2.53% |
| China International Capital Corp. Ltd. (Invt Management)as of 30 Sep 2023 | 29.11m | 1.77% |
| CITIC Securities Co., Ltd. (Invt Port)as of 31 Dec 2023 | 18.61m | 1.13% |
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 16.58m | 1.01% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 15.75m | 0.96% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 14.04m | 0.85% |
| Aegon-Industrial Fund Management Co., Ltd.as of 31 Dec 2023 | 11.68m | 0.71% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 10.11m | 0.61% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 9.29m | 0.56% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 7.76m | 0.47% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
